I. Executive Summary: The Great R&D Reset

The Contract Research Organization (CRO) industry is in the late stages of a cyclical downturn, precipitated by a severe contraction in biotech funding that began in 2022 and persisted through the first half of 2025. This “biotech winter” was a direct consequence of a fundamental shift in the macroeconomic landscape, as the end of the zero-interest-rate policy era forced a painful but necessary valuation reset for long-duration, high-risk assets. While near-term financial results for CROs will remain challenged by cautious client spending and elongated decision-making timelines, forward-looking indicators suggest a bottoming process is underway. A stabilization in pharma M&A activity and, most notably, an uptick in request-for-proposal (RFP) flow at industry bellwethers signal that underlying demand for R&D outsourcing remains structurally intact.

The impending recovery, which we believe will be catalyzed by a pivot in monetary policy, will not be uniform. A “flight to quality” is already evident, where market share and investor capital will consolidate around well-capitalized, technologically advanced, and diversified CROs that can offer integrated, data-driven solutions. This environment will separate the resilient market leaders from the more cyclically exposed players.

Key Findings

• The Biotech Funding Bottleneck: The biotech funding environment remains the primary constraint on the sector’s recovery. After a brief stabilization in Q1 2025, venture capital (VC) funding for biotechs declined sequentially in Q2 to its lowest level in three years.¹ The IPO window, a critical source of capital and a liquidity path for early investors, remains effectively closed, with poor post-listing performance deterring new entrants.²
• Divergent CRO Performance: Operational results are bifurcating across the CRO landscape. IQVIA’s diversified model, with its strong Technology & Analytics Solutions (TAS) segment, is providing significant resilience against the clinical downturn.⁴ In contrast, more traditional clinical CROs like ICON are facing revenue headwinds and the tangible impact of elevated contract cancellations, highlighting the risks of a less-diversified model.⁵
• Improving Leading Indicators: Despite the funding pressure, early signs of a demand recovery are emerging. IQVIA’s RFP flow grew in the low-teens year-over-year in Q2 2025, a powerful signal of future demand from both large pharma and emerging biotech clients.⁴
• The Monetary Policy Catalyst: A Federal Reserve pivot on interest rates is the most widely anticipated and impactful catalyst for a broad-based recovery. Lower rates are a prerequisite for easing financial conditions, boosting biotech valuations, and reopening capital flows into the sector.⁸

Top-Line Recommendations

Based on this analysis, an Overweight rating is initiated on IQVIA (IQV), reflecting its best-in-class diversification, technology leadership, and resilient financial model. Thermo Fisher (TMO) and Medpace (MEDP) are rated Market-Weight, acknowledging their strong operational models and recent performance, which now appear fairly valued. A cautious stance is taken on ICON (ICLR) and Charles River Labs (CRL), initiating with Underweight ratings due to their higher sensitivity to the biotech funding cycle and specific near-term operational pressures.

Recovery Scenario Probabilities

The following probabilities are assigned to the recovery timeline scenarios:

• Base Case (24-36 months): 60% Probability. A gradual recovery beginning in H2 2026, contingent on Federal Reserve rate cuts in late 2025 or early 2026.
• Best Case (12-18 months): 25% Probability. A V-shaped recovery spurred by earlier-than-expected rate cuts in H2 2025 and a sustained surge in large-scale pharma M&A.
• Bear Case (3-5 years): 15% Probability. An extended downturn caused by persistent inflation, a “higher for longer” interest rate environment, and a systemic, long-term reduction in VC risk appetite for the life sciences sector.

II. Anatomy of a Downturn: Unpacking the Headwinds

A. The Biotech Funding Winter: From Froth to Freeze

The current challenges facing the CRO industry are inextricably linked to the severe downturn in the biotech funding ecosystem. This “funding winter” represents a fundamental reset driven by the cost of capital, moving the sector from a period of unprecedented froth to a necessary, albeit painful, freeze.

Quantifying the Contraction

The flow of capital into the biopharma sector has contracted sharply since the peak in 2021. While overall funding showed a notable recovery in 2024, reaching a 10-year high of $102 billion (excluding the pandemic-era anomaly), this momentum has not been sustained into 2025.¹¹ The first half of 2025 has been a story of reversal. After a stable Q1, overall VC funding for biotechs plummeted from $7.0 billion to $4.8 billion in Q2, tying for the worst quarterly total in the last three years.¹ This sequential decline underscores the fragility of the funding environment.

The Choke Point – Capital Markets

The public capital markets, which serve as a vital source of funding for later-stage companies and an exit mechanism for early-stage investors, remain largely inaccessible. The biotech IPO window is effectively closed; only five companies went public in the first half of 2025, a stark contrast to the approximately 150 that listed during the 2020-2021 boom.² Investor appetite has been crushed by poor post-listing performance, with the vast majority of biotech IPOs since 2024 trading below their offering prices.³ This poor performance creates a negative feedback loop, deterring new companies from listing and trapping capital in late-stage private companies.

The Macro Driver – Federal Reserve Policy

The primary catalyst for this funding winter was the aggressive monetary tightening cycle initiated by the U.S. Federal Reserve in 2022. The rapid increase in interest rates fundamentally altered the valuation calculus for the biotech sector. Biotech companies, particularly those in the preclinical or early clinical stages, derive their value almost entirely from long-duration, high-risk future cash flows. As the risk-free rate rises, the discount rate used in net present value (NPV) models increases, disproportionately compressing the valuation of these long-duration assets.⁸ This is not merely a shift in sentiment but a mathematical reality. The move away from a zero-interest-rate policy (ZIRP) environment has eliminated the “There Is No Alternative” (TINA) trade that forced investors into high-risk assets. With safer assets now providing a positive real return, the incentive to fund speculative, cash-burning biotechs has significantly diminished, leading to a pronounced shift in VC risk appetite toward de-risked, later-stage companies with clearer paths to commercialization.¹⁴

Inflammatory Pressures

Compounding the funding challenges are direct operational cost pressures from inflation. The cost of conducting clinical trials is rising due to higher prices for raw materials, logistics, and, most significantly, skilled labor.¹⁷ A global shortage of qualified Clinical Research Associates (CRAs) and other specialized personnel is exacerbating wage inflation, acting as a direct restraint on CRO margins.¹⁸ Projections indicate that overall pharmacy spend will continue to climb by 3.8% through mid-2026, signaling that cost pressures within the broader healthcare ecosystem are persistent.¹⁷

Table 1: Biotech Funding Environment Tracker (2022-H1 2025)

Quarter	VC Funding ($B)	IPO Proceeds ($B)	Follow-on Offerings ($B)	Total Capital Raised ($B)	YoY % Change in Total
Q1 2024	$6.7	~$3.7	~$9.0	~$19.4	N/A
Q2 2024	$9.2	~$1.5	~$10.0	~$20.7	N/A
Q3 2024	$8.6	~$1.0	~$8.5	~$18.1	N/A
Q4 2024	$6.4	~$0.6	~$8.5	~$15.5	N/A
FY 2024	$30.9	~$6.8	~$36.0	~$73.7	+3.8%
Q1 2025	$7.0	~$2.6	~$9.5	~$19.1	-1.5%
Q2 2025	$4.8	~$0.9	~$8.0	~$13.7	-33.8%
Note: Data compiled and synthesized from sources.1 Follow-on offering data is estimated based on market reports. Q2 2025 IPO proceeds reflect a sharp decline in activity.

B. CRO Sector Under Pressure: A Bifurcated Reality

The direct consequence of the biotech funding slowdown is a challenging operating environment for CROs. However, the impact is not uniform. A clear bifurcation is emerging between diversified, scaled leaders who are weathering the storm and more specialized players who are bearing the full brunt of biotech’s financial constraints. This “flight to quality” among sponsors is reshaping the competitive landscape.

Decelerating Growth & Margin Compression

Financial results from Q2 2025 reveal the pressure on top-line growth. While some firms show resilience, the underlying trend is one of deceleration. IQVIA, the industry’s largest player, reported overall revenue growth of 5.3%, but its core Research & Development Solutions (R&DS) segment grew by a modest 2.5% (or 1.3% at constant currency).⁴ The situation is more acute for less diversified firms; ICON reported a year-over-year revenue decline of 4.8% for the same period.⁵ Looking ahead, consensus estimates for Charles River Labs (CRL), a bellwether for the preclinical market, project a 10.7% year-over-year decline in Q2 EPS, reflecting the direct impact of reduced early-stage R&D spending.²⁰

Diverging Demand Signals – Bookings & Backlog

Forward-looking demand indicators, while still reflecting a cautious environment, show early signs of stabilization and divergence among competitors.

• IQVIA: The company demonstrated notable strength in Q2, posting a healthy net book-to-bill ratio of 1.12x and growing its industry-leading backlog to a record $32.1 billion, up 5.1% year-over-year. Most importantly, management commentary pointed to a meaningful uptick in demand, with RFP flow growing in the low-teens year-over-year, driven by all customer segments.⁴
• ICON: In contrast, ICON posted a weaker net book-to-bill of 1.02x. While gross bookings showed sequential improvement, the net figure was weighed down by the significant issue of elevated cancellations.⁵
• Charles River Labs: For the preclinical segment, CRL provided a positive signal in Q1 2025, reporting that its Discovery and Safety Assessment (DSA) segment’s net book-to-bill ratio returned to above 1.0x for the first time in over two years.²²

The Cancellation Conundrum

Elevated contract cancellations have emerged as a key headwind and a barometer of client financial distress. ICON’s Q2 performance was materially impacted by the cancellation of a single large next-generation COVID vaccine trial, which not only reduced its net bookings but also highlighted the risk concentration within its backlog.⁶ Management expects these elevated cancellation levels to persist in the near term, suggesting ongoing portfolio reprioritization and financial pressure among its clients.⁵ Monitoring this metric across the industry will be critical to gauging the health of the recovery.

Client Concentration & Mix

The downturn underscores the strategic importance of a diversified client base. CROs with a balanced mix between large, well-capitalized pharmaceutical companies and smaller, emerging biotechs are proving more resilient. Large pharma, while managing its own budgets, has more stable R&D spending patterns compared to the SMID-cap biotech segment, which is almost entirely dependent on the volatile capital markets for funding. This bifurcation in client health is a primary driver of the performance gap between different CROs.

Table 2: CRO Operational Metrics Scorecard (Q2 2025)

Company	Q2’25 Revenue YoY (%)	Q2’25 R&D/Clinical Rev YoY (%)	TTM Book-to-Bill Ratio	Q2’25 Backlog Growth YoY (%)	Q2’25 Adj. EBITDA Margin (%)	Analyst Commentary
IQVIA (IQV)	5.3%	2.5%	1.10x	5.1%	22.7%	Strong RFP flow (+low teens YoY) and record backlog signal recovery. TAS segment provides crucial diversification. 4
Thermo Fisher (TMO)	3.0%	Mid-single digit	N/A	N/A	21.9%	Pharma & Biotech segment was a key growth driver. Integrated CDMO/CRO model offers synergies. 23
ICON plc (ICLR)	(4.8%)	(4.8%)	1.01x (YTD)	N/A	19.6%	Revenue declined; net bookings impacted by elevated cancellations. Cautious outlook despite some biotech RFP uptick. 5
Charles River (CRL)	N/A (Est. (2.5%))	N/A (DSA Est. flat)	>1.0x (Q1)	N/A	N/A (Est. 19.0%)	Q1 showed demand stabilization. High exposure to early-stage biotech remains a key risk. Q2 results pending. 20
Medpace (MEDP)	14.2%	14.2%	1.03x	(1.8%)	21.6%	Exceptional growth driven by shift to faster-burning therapeutic areas. Raised FY25 guidance significantly. 25
Note: Data from company earnings reports.4 CRL Q2 data is estimated based on analyst consensus and Q1 results as the report is not yet released. TMO revenue is for the entire company; segment growth is noted in commentary.

C. The Big Pharma Paradox: Cautious Spending Amidst a Looming Patent Cliff

While the biotech funding winter is the acute problem, the strategic posture of large pharmaceutical companies provides a crucial, stabilizing long-term tailwind for the CRO industry. Big Pharma is navigating a paradox: the need to manage costs and R&D budgets in an uncertain macroeconomic environment while simultaneously confronting a historic patent cliff that necessitates aggressive pipeline replenishment.

The Build vs. Buy Framework

The pharmaceutical industry is facing an unprecedented wave of patent expirations, with an estimated $350 billion in revenue at risk between 2025 and 2029.²⁸ This revenue gap is too large to be filled solely through internal R&D, where productivity remains a persistent challenge. The internal rate of return on R&D investment for large biopharma has fallen to a mere 4.1%, well below the cost of capital, making large internal R&D investments less attractive.²⁸ This dynamic forces a strategic shift towards a “buy” over “build” strategy, where external innovation is acquired through M&A and licensing deals to supplement internal efforts.²⁸

Outsourcing as a Strategic Imperative

This reliance on external innovation reinforces the structural trend of R&D outsourcing. Even as pharma companies scrutinize internal budgets, outsourcing to CROs and CDMOs provides critical flexibility, access to specialized expertise, and cost efficiencies. Data shows that from 2014 to 2022, spending on CROs and CDMOs grew at an annual rate of 12-13%, significantly outpacing the 7-8% annual growth in overall R&D spending.³⁰ A recent McKinsey survey found that over 80% of pharma leaders expect this trend to accelerate, projecting a 10-30% rise in supplier spending over the next five years.³⁰ This structural tailwind provides a resilient floor for CRO demand, mitigating some of the cyclical pressures from the biotech segment.

M&A Activity as a Leading Indicator

The execution of the “buy” strategy is evident in the M&A landscape. The first half of 2025 saw robust deal-making, with several multi-billion dollar transactions, including Johnson & Johnson’s $14.6 billion acquisition of Intra-Cellular Therapies and Merck KGaA’s $3.9 billion deal for SpringWorks Therapeutics.³¹ This activity is a critical leading indicator for the health of the entire R&D ecosystem. These deals provide a vital infusion of non-dilutive capital to the acquired biotech companies and, more importantly, return capital to their VC backers. This liquidity allows VCs to realize returns and redeploy that capital into new early-stage ventures, effectively restarting the funding cycle that ultimately fuels CRO growth.¹

III. The Path to Recovery: Leading Indicators and Catalysts

While the current environment remains challenging, a recovery is inevitable, driven by the non-discretionary nature of developing life-saving medicines. The key for investors is to identify the leading indicators that will signal a definitive turn in the cycle and understand the primary catalysts that will drive it. The recovery will not be simultaneous across all segments; it will follow a predictable sequence, offering opportunities for well-positioned investors to anticipate the rebound in CRO fundamentals.

A. Leading Indicators Dashboard: Reading the Tea Leaves

Monitoring a specific set of metrics will be crucial to tracking the recovery’s progress.

• Biotech Funding Pipeline: The earliest signal will come from the private markets. A sustained increase in the volume and value of early-stage (Seed and Series A) financing rounds would indicate a thawing of VC risk appetite. While venture funds hold record levels of “dry powder”—uninvested capital—exceeding $310 billion, the pace of deployment has been sluggish.³² An acceleration in this deployment rate, coupled with a stabilization or increase in pre-money valuations, would be the first green shoot.
• Clinical Trial Activity: An increase in funding will translate directly into R&D activity. Tracking new clinical trial starts on registries like clinicaltrials.gov, with a specific focus on Phase I and II studies, is a direct measure of biotech R&D spend. After trial starts returned to pre-pandemic levels in 2024 with 5,318 initiations, a sustained year-over-year increase through 2025 would confirm that new capital is being put to work.¹¹ Oncology, Central Nervous System (CNS), and Cardiovascular diseases are expected to continue leading in trial volume.³⁴
• CRO Demand Metrics: The most direct forward-looking indicator for the CRO industry is Request for Proposal (RFP) volume. IQVIA’s reported low-teens year-over-year growth in Q2 RFP flow is the most significant positive data point to emerge thus far.⁴ Confirmation of this trend from other major CROs in their upcoming earnings reports would signal a broad-based recovery in demand. A sustained period of industry-wide net book-to-bill ratios consistently above 1.2x would mark a definitive inflection point from stabilization to expansion.
• Regulatory Environment: A stable and predictable regulatory landscape is essential for investor confidence. Key metrics include FDA novel drug approval numbers and the issuance of Breakthrough Therapy Designations. In the first half of 2025, the FDA’s Center for Drug Evaluation and Research (CDER) approved 16 novel drugs, pacing slightly behind 2024.³⁵ A steady or accelerating pace of approvals, particularly for innovative therapies, would provide a positive backdrop for investment.

B. Primary Catalysts for a Cyclical Rebound

Three primary catalysts are expected to drive the recovery cycle.

• The Fed Pivot (The “When, Not If” Catalyst): A definitive shift to a more accommodative monetary policy by the U.S. Federal Reserve is the single most important catalyst. A reduction in the federal funds rate will lower the cost of capital across the economy. This has a dual benefit for biotech: it directly boosts valuations by lowering the discount rate applied to future earnings, and it encourages a “risk-on” sentiment among investors, driving capital flows back into growth-oriented sectors.⁹ Historical analysis shows that the biotech sector has, on average, outperformed the S&P 500 by 16% in the 12 months following the first rate cut in a new cycle.¹⁰
• Pharma M&A as a Funding Engine: The strategic imperative for large pharma to address the 2025-2030 patent cliff through acquisitions is a powerful secondary catalyst.²⁸ The robust M&A activity seen in H1 2025 is expected to continue, providing a crucial source of non-dilutive funding for the biotech ecosystem.³¹ Each acquisition not only validates the acquired technology but also returns significant capital to VC investors, which is then available for reinvestment into new companies, creating a virtuous cycle of innovation and funding.¹
• Breakthrough Innovation: Sentiment in the biotech sector is highly sensitive to clinical trial news. A major drug approval or positive late-stage data in a high-value therapeutic area can reignite investor enthusiasm and attract generalist capital back into the sector. Key areas to watch for such catalysts include next-generation oncology treatments like Antibody-Drug Conjugates (ADCs) and cell therapies, novel approaches in CNS disorders like Alzheimer’s disease, and advances in rare disease treatments.³⁸

C. Recovery Timeline Scenarios

The timing and pace of the recovery will depend on the interplay of these catalysts. Three potential scenarios are outlined below.

• Best Case (Recovery begins H1 2026; 25% Probability): This scenario assumes the Federal Reserve begins aggressively cutting interest rates in late 2025 in response to a cooling economy. This, combined with a continued surge in large-scale pharma M&A, leads to a rapid reopening of the biotech IPO window by mid-2026. VC funding accelerates sharply, driving CRO book-to-bill ratios to consistently exceed 1.3x by the end of 2026, with revenue growth re-accelerating in H1 2027.
• Base Case (Gradual recovery over 24-36 months; 60% Probability): This scenario assumes the Fed begins a slow, measured cutting cycle in early 2026. VC funding gradually thaws throughout 2026, leading to a modest pickup in Phase I/II trial starts in the second half of the year. The IPO window begins to crack open for high-quality, late-stage companies. CRO revenue growth bottoms out in 2026 and begins to re-accelerate to mid-single-digit growth in 2027.
• Bear Case (Extended downturn of 3-5 years; 15% Probability): This scenario assumes that inflation remains stubbornly high, forcing the Fed to maintain a “higher for longer” interest rate policy through 2026. The biotech funding winter extends, leading to a significant number of biotech company failures and a structural downsizing of the industry. CROs would face multiple years of flat to low-single-digit growth, intense pricing pressure, and significant margin compression.

Table 3: Recovery Timeline & Leading Indicators (Base Case Scenario)

Indicator	Q3’25	Q4’25	Q1’26	Q2’26	Q3’26	Q4’26
Fed Funds Rate (Target)	4.75-5.00%	4.75-5.00%	4.50-4.75%	4.25-4.50%	4.00-4.25%	3.75-4.00%
Biotech VC Funding ($B/qtr)	$5.5B	$6.5B	$7.5B	$8.5B	$9.5B	$11.0B
Biotech IPOs (#/qtr)	1-2	2-3	3-5	5-7	7-10	10-12
Pharma M&A ($B/qtr)	$20B	$25B	$30B	$35B	$30B	$40B
Phase I/II Trial Starts (YoY %)	-5%	0%	+5%	+8%	+12%	+15%
CRO Avg. Book-to-Bill	1.05x	1.10x	1.15x	1.20x	1.25x	1.30x
Note: This table presents quantitative forecasts under the Base Case scenario. Best Case would see metrics accelerate 2-3 quarters earlier. Bear Case would see metrics remain flat or decline through 2026.

IV. Investment Analysis: Ranking the CROs

The current market environment necessitates a discerning approach to investing in the CRO sector. The analysis moves beyond a top-down industry view to a bottom-up evaluation of individual companies, focusing on business model resilience, competitive positioning, and valuation. A clear hierarchy has emerged, favoring scaled, diversified players over more cyclically exposed peers.

A. Large-Cap Leaders: Stability and Scale

• IQVIA (IQV)

• Rating: Overweight
• Price Target: $235
• Investment Thesis: The investment thesis for IQVIA is centered on its best-in-class diversification and technology leadership, which provide a durable competitive advantage and a resilient financial profile. The company’s structure is unique among its peers, with two powerful, synergistic segments: Research & Development Solutions (R&DS) and Technology & Analytics Solutions (TAS). The TAS segment, which provides data, analytics, and real-world evidence services, is a high-growth, high-margin business that is less correlated with the biotech funding cycle. Its performance is driven by the commercialization needs of large pharma clients, providing a stable engine of growth that buffers the cyclicality of the clinical R&D business. This was evident in Q2 2025, where TAS revenue grew a robust 8.9% year-over-year, offsetting the modest 2.5% growth in R&DS.⁴ Furthermore, IQVIA’s aggressive investment in AI and data platforms is not just a talking point; it is a core part of its strategy to enhance efficiency and create a competitive moat.⁷ Forward-looking indicators for its core clinical business are strong; the Q2 book-to-bill ratio of 1.12x and a record $32.1 billion backlog, combined with management’s report of low-teens year-over-year growth in RFP flow, signal that an inflection in the R&DS segment is approaching.⁴ The company’s balance sheet is manageable, with a net leverage ratio of 3.61x, and management has demonstrated a commitment to shareholder returns through a significant share repurchase program, buying back over $1 billion in stock year-to-date.⁴ While its valuation is not the cheapest in the sector, the premium is justified by its superior, more resilient business model.
• Thermo Fisher (TMO – PPD Segment)

• Rating: Market-Weight
• Price Target: $480
• Investment Thesis: The investment case for Thermo Fisher’s CRO business is built on the unparalleled scale and synergy created by the integration of PPD into the broader TMO ecosystem. This combination creates a unique end-to-end offering that spans from life sciences tools and diagnostics to clinical trial services and contract manufacturing. A key differentiator is the company’s “Accelerator” drug development solution, which integrates CDMO and CRO capabilities and has been shown to significantly shorten development timelines for clients.⁴² The company’s Q2 2025 results were strong, with overall revenue of $10.85 billion beating estimates and management raising full-year guidance.²³ The pharma and biotech end market was a source of strength, delivering mid-single-digit growth during the quarter.²³ However, the stock’s premium valuation reflects these strengths, and the broader TMO entity is exposed to macroeconomic headwinds in other segments, such as slowing academic and government research funding.²³ The balance sheet is solid, with a debt-to-equity ratio of 0.69, supporting its strategy of growth through both organic investment and strategic acquisitions.⁴⁴ The current valuation appears to fairly balance the strong competitive position of the PPD segment against the broader risks facing the parent company, warranting a Market-Weight rating.
• Charles River Labs (CRL)

• Rating: Underweight
• Price Target: $160
• Investment Thesis: Charles River Labs holds a dominant position in the preclinical CRO market and the research models segment. While this provides a recurring revenue stream, it also creates a concentrated exposure to the earliest and most volatile stage of the R&D funding cycle. The company’s performance is highly sensitive to the financial health of the SMID-cap biotech sector. Analysts are forecasting a 10.7% year-over-year decline in Q2 2025 EPS, reflecting this pressure.²⁰ Although the company posted better-than-expected Q1 results and modestly raised its full-year 2025 guidance, and its DSA segment book-to-bill ratio recovered to above 1.0x, significant uncertainties remain.²⁰ Lingering concerns about the global supply chain for non-human primates (NHPs) and weakness in its Manufacturing Solutions segment present ongoing risks. The current valuation does not appear to fully discount the potential for a prolonged period of cautious spending from its core biotech client base, leading to an Underweight rating.
• ICON plc (ICLR)

• Rating: Underweight
• Price Target: $165
• Investment Thesis: ICON’s Q2 2025 results were disappointing and highlighted the challenges facing more traditional, clinically-focused CROs in the current environment. The 4.8% year-over-year revenue decline was coupled with a weak net book-to-bill ratio of 1.02x, which was significantly impacted by elevated contract cancellations.⁵ The cancellation of a single large COVID vaccine trial underscores the potential for volatility within its backlog and the risks of client and project concentration.⁶ While management noted a modest uptick in RFP flow from biotech clients, their commentary that elevated cancellations will likely persist in the near term is a significant concern.⁶ The company amended its full-year guidance, raising the revenue midpoint but holding the EPS midpoint steady, which implies ongoing margin pressure likely from a mix shift toward lower-margin pass-through costs.⁶ Although the stock trades at a discount to peers on forward earnings multiples, the near-term risks to revenue and earnings are elevated until there is clear evidence that cancellations are normalizing and that the biotech funding environment is on a sustainable recovery path.

B. Mid-Cap Specialists: Differentiated Models

• Medpace (MEDP)

• Rating: Market-Weight
• Price Target: $480
• Investment Thesis: Medpace delivered an exceptionally strong second quarter, with revenue and EPS soundly beating consensus estimates, which catalyzed a stock surge of over 50%.²⁵ Revenue grew 14.2% year-over-year, a standout performance in the current environment. This growth was driven by a strategic mix shift toward faster-burning therapeutic areas, such as metabolic studies, and away from longer-cycle oncology trials, as well as fewer project cancellations as the funding environment for its clients stabilized.²⁵ The company’s differentiated, physician-led model and disciplined operational focus have allowed it to maintain industry-leading margins (21.6% EBITDA margin in Q2).²⁵ Management issued a significant raise to its full-year 2025 guidance, signaling strong confidence in continued momentum.²⁶ While Medpace’s high-growth profile and focus on the innovative SMID-cap biotech segment make it a prime beneficiary of an eventual market recovery, its stock price now largely reflects this optimism. After the dramatic re-rating, the risk/reward profile appears balanced, warranting a Market-Weight rating.
• Syneos Health (SYNH)

• Rating: Not Rated (Private)
• Analysis: Syneos Health was acquired and taken private in September 2023 by a consortium of private equity firms, including Elliott Investment Management.⁴⁹ Prior to the acquisition, the company’s key differentiator was its unique “biopharmaceutical acceleration” model, which sought to integrate clinical development (CRO) and commercialization (CSO) services. This model aimed to provide clients with a seamless solution from “lab to life.” Since going private, the company is likely undergoing a significant strategic and operational transformation focused on improving efficiency, investing in technology, and refining its integrated service offering to better compete with larger rivals.⁵⁰ While no longer a public investment vehicle, its strategic actions, partnerships, and competitive posture will continue to influence the market dynamics for the publicly traded peer group.⁵¹

Table 4: CRO Valuation & Ratings Summary

Company (Ticker)	Current Price (as of 7/24/25)	Market Cap ($B)	Fwd. P/E (NTM)	Fwd. EV/EBITDA (NTM)	12-Month Price Target	Implied Upside/Downside (%)	Rating
IQVIA (IQV)	$194.24	$33.0	~16.5x	~11.8x	$235.00	+21.0%	Overweight
Thermo Fisher (TMO)	$479.02	$179.5	~21.3x	~16.5x	$480.00	+0.2%	Market-Weight
Charles River (CRL)	$168.50	$8.7	~17.4x	~11.5x	$160.00	-5.0%	Underweight
ICON plc (ICLR)	$164.00	$13.5	~12.1x	~9.5x	$165.00	+0.6%	Underweight
Medpace (MEDP)	$477.73	$13.4	~32.7x	~23.1x	$480.00	+0.5%	Market-Weight
Note: Current prices are as of market close on July 24, 2025. Forward multiples are based on consensus estimates for the next twelve months. Price targets are internally generated.

V. Identifying the Rebound Beneficiaries: Strategic Biotech & Tech Enablers

Beyond the CROs, the eventual recovery in R&D spending will lift the fortunes of well-positioned biotech companies and the technology firms that enable their research. A strategic approach to this segment involves identifying companies with de-risked assets and the technology platforms that will define the next wave of innovation.

A. Biotech Portfolio Strategy: Positioning for the Thaw

As the funding environment improves, capital will not flow indiscriminately. Investors will prioritize companies with clear value propositions and reduced risk profiles.

• Well-Funded, Late-Stage Companies: The most immediate beneficiaries of a market recovery will be companies with assets that are close to key clinical milestones or commercial launch. These companies have a shorter path to generating revenue and are less dependent on early-stage funding. Companies with positive Phase 3 data in 2025, such as Boehringer Ingelheim’s zongertinib (HER2-mutant lung cancer) and nerandomilast (pulmonary fibrosis), exemplify the type of late-stage assets that will attract capital and potential M&A interest.⁵⁴
• Breakthrough Therapy Designation Holders: An FDA Breakthrough Therapy Designation is a powerful validation signal, indicating that a drug has shown substantial improvement over available therapies for a serious condition. This can expedite development and review timelines, de-risking the asset. Companies that have recently received this designation, such as Avidity Biosciences for del-zota in Duchenne muscular dystrophy and Revolution Medicines for elironrasib in KRAS G12C non-small cell lung cancer, represent high-impact innovation and are attractive investment targets.⁵⁶
• Strong Big Pharma Partnerships: Biotechs with significant, well-structured partnerships with large pharmaceutical companies benefit from non-dilutive funding, external scientific validation, and access to development and commercial expertise. These collaborations reduce financial risk and increase the probability of success.
• Trading Below Cash with Quality Assets: During market downturns, a subset of companies can trade at a market capitalization below their net cash on the balance sheet. This creates a compelling deep-value opportunity if the company possesses a quality clinical pipeline. Screening for these situations can yield high-return investments, as any positive clinical news can lead to a significant re-rating of the stock.

B. Thematic Opportunities in Technology: The R&D Enablers

The next cycle of R&D investment will be heavily influenced by technology, creating opportunities in the sub-sectors that provide the tools for more efficient drug development.

• AI-Driven Drug Discovery: The market for AI in drug discovery is poised for explosive growth, with forecasts projecting a CAGR of over 27% to 37% through 2030.⁵⁸ Platforms that leverage artificial intelligence and machine learning to accelerate target identification, design novel molecules, and predict clinical success are transforming the economics of early-stage R&D. These technologies can reduce timelines and failure rates, making them a critical area of investment for both pharma and VC funds.⁶⁰
• Clinical Trial Management & Decentralization: The adoption of Decentralized Clinical Trials (DCTs) is a permanent, structural shift accelerated by the pandemic. The DCT market is expected to more than double, reaching $18.6 billion by 2030, representing a CAGR of nearly 15%.⁶² This creates a significant opportunity for companies that provide the enabling technologies, including wearable sensors, electronic Patient-Reported Outcome (ePRO) platforms, telehealth services, and the cloud-based software required to manage complex remote data streams. These tools are essential for improving patient recruitment, enhancing data quality, and making trials more accessible and efficient.⁶³

VI. Risk Assessment & Portfolio Construction

While the analysis points toward an eventual recovery, investors must remain cognizant of the significant risks that could delay or derail this thesis. A disciplined portfolio strategy is required to balance the potential for high returns with the inherent volatility of the sector.

A. Downside Risks to the Thesis

• Extended Biotech Funding Winter: The primary risk is that the base case scenario is too optimistic. A period of persistent inflation could force the Federal Reserve to maintain a “higher for longer” interest rate policy, further extending the biotech funding winter.⁶⁵ This would lead to a higher rate of biotech company failures, increased pressure on CRO pricing, and a prolonged period of stagnant growth.
• Regulatory Tightening: A more stringent regulatory environment at the FDA could increase the cost and complexity of drug development. Heightened scrutiny of clinical trial data, particularly for drugs seeking accelerated approval, or new requirements for trial protocol design could raise the bar for success, dampening investor enthusiasm and slowing innovation.²⁸
• Technology Disruption: While AI and automation present an opportunity, they also pose a disruptive threat to the traditional, labor-intensive business models of some CROs. If technological adoption allows for a significant reduction in the human capital required to run clinical trials faster than incumbents can adapt, it could lead to severe margin compression for those who fail to innovate.⁶⁷
• Geopolitical & Macroeconomic Shock: A severe global recession would impact healthcare spending and reduce the overall appetite for risk among investors. Furthermore, escalating geopolitical tensions, particularly those leading to new tariffs on pharmaceutical products or disruptions to the global supply chain, could introduce new costs and uncertainties into the R&D process.³⁷

B. Upside Opportunities

• Accelerated Market Share Consolidation: A prolonged downturn could act as a catalyst for M&A within the CRO industry itself. The strongest players, like IQVIA and Thermo Fisher, could leverage their balance sheets to acquire smaller, struggling competitors or complementary technology assets at attractive valuations, emerging from the cycle with even greater market power and an enhanced competitive moat.⁷⁰
• Significant Operating Leverage: The CRO business model possesses significant operating leverage. As the demand environment improves and revenue growth re-accelerates, companies that have effectively managed their cost structures during the downturn will experience a rapid expansion in operating margins, leading to faster-than-expected earnings growth.
• Emergence of New Therapeutic Modalities: While the funding environment for complex modalities like cell and gene therapy is currently challenged, a scientific breakthrough in one of these areas could unlock a vast new addressable market. This would create a multi-year growth tailwind for specialized CROs with the expertise to support the development of these novel therapies.³⁸

C. Proposed Portfolio Construction

For investors seeking to capitalize on the eventual recovery in the CRO and biotech R&D sector, a barbell strategy is recommended. This approach balances the stability of established market leaders with the higher growth potential of more cyclically sensitive names and innovative biotechs.

• Core Holdings (60%): The portfolio should be anchored with an Overweight position in IQVIA (IQV). Its diversified business model, strong balance sheet, and leadership in technology and data analytics provide a defensive foundation with exposure to the recovery in clinical R&D.
• Growth Holdings (25%): A Market-Weight allocation to Medpace (MEDP) provides exposure to a higher-growth, higher-beta business model. Its focus on the SMID-cap biotech segment means it will benefit disproportionately from a cyclical upswing in funding, as demonstrated by its recent stock performance.
• Speculative Basket (15%): A diversified basket of 5-7 select biotech companies should be constructed, focusing on the categories identified in Section V.A (e.g., late-stage assets, recent Breakthrough Therapy Designations). This allocation provides exposure to the high-upside potential of successful clinical development, while diversification mitigates single-asset risk.
• Underweight/Avoid: A cautious stance is advised for companies with higher direct exposure to the most distressed segments of the biotech market or those facing specific operational headwinds. Positions in ICON plc (ICLR) and Charles River Labs (CRL) should be underweighted or avoided until there is clearer evidence of a sustained recovery in their core end markets and a resolution to their company-specific challenges.

Works cited

1. Biotech startup funding dried up in second quarter, HSBC finds – BioPharma Dive, accessed July 25, 2025, https://www.biopharmadive.com/news/biotech-venture-capital-funding-h1-2025-hsbc/753283/
2. Can Biotech be Resilient in the Face of Uncertainty? | BDO – BDO USA, accessed July 25, 2025, https://www.bdo.com/insights/industries/life-sciences/bdo-biotech-brief-summer-2025
3. Biotech IPO market faces sharp slowdown in 2025 – Tech in Asia, accessed July 25, 2025, https://www.techinasia.com/news/biotech-ipo-market-faces-sharp-slowdown-2025
4. IQVIA Reports Second-Quarter 2025 Results – Investor Relations, accessed July 25, 2025, https://ir.iqvia.com/press-releases/press-release-details/2025/IQVIA-Reports-Second-Quarter-2025-Results/default.aspx
5. Icon PLC (ICLR) Q2 2025 Earnings Call Highlights: Navigating Cha – GuruFocus, accessed July 25, 2025, https://www.gurufocus.com/news/3004512/icon-plc-iclr-q2-2025-earnings-call-highlights-navigating-challenges-with-strategic-wins
6. ICON Public Limited Company (ICLR) Q2 2025 Earnings Call …, accessed July 25, 2025, https://seekingalpha.com/article/4804242-icon-public-limited-company-iclr-q2-2025-earnings-call-transcript
7. IQVIA Holdings Inc. (IQV) Q2 2025 Earnings Call Transcript …, accessed July 25, 2025, https://seekingalpha.com/article/4803173-iqvia-holdings-inc-iqv-q2-2025-earnings-call-transcript
8. Taxes, tariffs and interest rates hold key to biotech’s future amid uncertain outlook: EY, accessed July 25, 2025, https://www.fiercebiotech.com/biotech/uncertainty-reigns-business-remains-hold-ey-says-its-annual-biotech-report
9. Can the Fed’s rate cut change biotech’s ‘new normal’? | BioPharma Dive, accessed July 25, 2025, https://www.biopharmadive.com/news/biotech-interest-rates-impact-startups-venture-capital/727479/
10. Biotech sector update: Going for gold – Janus Henderson Investors – US Advisor, accessed July 25, 2025, https://www.janushenderson.com/en-us/advisor/article/biotech-sector-update-going-for-gold/
11. Global Trends in R&D 2025: Signs of Higher Efficiency and Productivity – IQVIA, accessed July 25, 2025, https://www.iqvia.com/blogs/2025/06/global-trends-in-r-and-d-2025-signs-of-higher-efficiency-and-productivity
12. Interest Rate Cuts: A Lifeline for Emerging Biotech Companies in 2025 – Prestige Scientific, accessed July 25, 2025, https://www.prestigescientific.com/market-mastery/interest-rate-cuts-a-lifeline-for-emerging-biotechs-in-2025
13. Biotech R&D crunch: The impact of the Inflation Reduction Act and economic challenges – Labiotech.eu, accessed July 25, 2025, https://www.labiotech.eu/trends-news/rd-crunch-amid-spending-cuts/
14. 2025 Trends in Biotech Venture Capital Funding – Excedr, accessed July 25, 2025, https://www.excedr.com/blog/trends-in-biotech-venture-capital-funding
15. Biotech 2025 Funding Squeeze, How to Navigate – BioBridge Global, accessed July 25, 2025, https://biobridgeglobal.org/industry/navigating-the-2025-biotech-funding-squeeze/
16. Investor Caution Leads to Dip in Biotech Financings, GlobalData …, accessed July 25, 2025, https://medcitynews.com/2025/05/biotech-financings-startups-investing-venture-capital/
17. Healthcare supply chain, pharmacy costs to rise in 2025: report …, accessed July 25, 2025, https://www.healthcaredive.com/news/healthcare-supply-chain-pharmacy-costs-rise-2025-report/738928/
18. Contract Research Organization Market Size, Industry Trends & Share 2030, accessed July 25, 2025, https://www.mordorintelligence.com/industry-reports/contract-research-organization-market
19. IQVIA revenue up 5.3% to USD 4017M in Q2 2025 – Medical Buyer, accessed July 25, 2025, https://medicalbuyer.co.in/iqvia-revenue-up-5-3-to-usd-4017m-in-q2-2025/
20. Here’s What to Expect From Charles River Laboratories’ Next Earnings Report – Cooper Farms, Inc -, accessed July 25, 2025, https://www.cooperfarmsgrain.com/news/story/33491892/here-s-what-to-expect-from-charles-river-laboratories-next-earnings-report
21. Here’s What To Expect From Charles River Laboratories’ Next Earnings Report, accessed July 25, 2025, https://www.barchart.com/story/news/33491891/here-s-what-to-expect-from-charles-river-laboratories-next-earnings-report
22. Charles River Laboratories International, Inc. (NYSE:CRL) Q1 2025 Earnings Call Transcript, accessed July 25, 2025, https://www.insidermonkey.com/blog/charles-river-laboratories-international-inc-nysecrl-q1-2025-earnings-call-transcript-1528042/
23. Earnings call transcript: Thermo Fisher beats Q2 2025 forecasts, stock surges, accessed July 25, 2025, https://www.investing.com/news/transcripts/earnings-call-transcript-thermo-fisher-beats-q2-2025-forecasts-stock-surges-93CH-4148536
24. Thermo Fisher Scientific Inc (TMO) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges – GuruFocus, accessed July 25, 2025, https://www.gurufocus.com/news/3000144/thermo-fisher-scientific-inc-tmo-q2-2025-earnings-call-highlights-strong-revenue-growth-amid-market-challenges
25. Earnings call transcript: Medpace’s Q2 2025 earnings surpass expectations By Investing.com, accessed July 25, 2025, https://www.investing.com/news/transcripts/earnings-call-transcript-medpaces-q2-2025-earnings-surpass-expectations-93CH-4146409
26. Medpace Holdings, Inc. Reports Second Quarter 2025 Results, accessed July 25, 2025, https://investor.medpace.com/news-releases/news-release-details/medpace-holdings-inc-reports-second-quarter-2025-results/
27. Charles River Laboratories Announces First-Quarter 2025 Results – Investor Relations, accessed July 25, 2025, https://ir.criver.com/news-releases/news-release-details/charles-river-laboratories-announces-first-quarter-2025-results/
28. Biopharma R&D Faces Productivity And Attrition Challenges In 2025 – Clinical Leader, accessed July 25, 2025, https://www.clinicalleader.com/doc/biopharma-r-d-faces-productivity-and-attrition-challenges-in-2025-0001
29. Biopharma’s Biggest Bets in 2025 Are All About M&A, accessed July 25, 2025, https://www.healthcarein.org/post/biopharma-s-biggest-bets-in-2025-are-all-about-m-a
30. Building a shared vision for pharma R&D–supplier … – McKinsey, accessed July 25, 2025, https://www.mckinsey.com/industries/life-sciences/our-insights/building-a-shared-vision-for-pharma-r-and-d-supplier-partnerships
31. Pharma and Biotech M&As in 2025 Roundup – Xtalks, accessed July 25, 2025, https://xtalks.com/pharma-and-biotech-mas-in-2025-roundup-4105/
32. Quarter Starts with Tariffs, Ends with Some Welcome High-Profile Exits – EisnerAmper, accessed July 25, 2025, https://www.eisneramper.com/insights/financial-services/venture-capital-quarter-2-outlook-0725/
33. Private Equity and Venture Capital Trends in 2025, accessed July 25, 2025, https://www.crystalfunds.com/insights/private-equity-and-venture-capital-trends-2025
34. The clinical landscape for 2025 – Oximio, accessed July 25, 2025, https://oximio.com/wp-content/uploads/2025/01/Clinical-Trial-Trends-2025.pdf
35. New medications coming soon: Here’s what’s been FDA approved in 2025 so far – KVIA, accessed July 25, 2025, https://kvia.com/news/2025/07/25/new-medications-coming-soon-heres-whats-been-fda-approved-in-2025-so-far/
36. FDA Approval Stats: Trends in First Generics, Biosimilars, and More …, accessed July 25, 2025, https://www.goodrx.com/drugs/news/recent-fda-approval-statistics
37. Pharmaceutical and life sciences: US Deals 2025 midyear outlook – PwC, accessed July 25, 2025, https://www.pwc.com/us/en/industries/health-industries/library/pharma-life-sciences-deals-outlook.html
38. 2025 Biotech Economics: CROs, Advanced Therapies & Trends in Funding, accessed July 25, 2025, https://www.precisionformedicine.com/blog/2025-biotech-economics-cros-advanced-therapies-trends-in-funding
39. Five Key Trends Shaping Biopharma and Biotech in 2025 – PPD, accessed July 25, 2025, https://www.ppd.com/blog/2025-biopharma-biotech-trends/
40. Alzheimer’s disease drug development pipeline: 2025 – PMC – PubMed Central, accessed July 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12131090/
41. IQVIA Q2 2025 slides: revenue up 5.3%, AI innovation drives growth – Investing.com, accessed July 25, 2025, https://www.investing.com/news/company-news/iqvia-q2-2025-slides-revenue-up-53-ai-innovation-drives-growth-93CH-4146362
42. Thermo Fisher Scientific Reports Second Quarter 2025 Results, accessed July 25, 2025, https://ir.thermofisher.com/investors/news-events/news/news-details/2025/Thermo-Fisher-Scientific-Reports-Second-Quarter-2025-Results
43. Thermo Fisher Scientific Reports Second Quarter 2025 Results, accessed July 25, 2025, https://ir.thermofisher.com/investors/news-events/news/news-details/2025/Thermo-Fisher-Scientific-Reports-Second-Quarter-2025-Results/
44. Thermo Fisher’s Strong Q2 Performance and Revised Guidance: A Buy Signal Amid a Challenging Sector? – AInvest, accessed July 25, 2025, https://www.ainvest.com/news/thermo-fisher-strong-q2-performance-revised-guidance-buy-signal-challenging-sector-2507/
45. Growth or Bubble? Thermo Fisher’s Market Moves – StocksToTrade, accessed July 25, 2025, https://stockstotrade.com/news/thermo-fisher-scientific-inc-tmo-news-2025_07_23/
46. ICON Reports Second Quarter 2025 Results, accessed July 25, 2025, https://investor.iconplc.com/news-releases/news-release-details/icon-reports-second-quarter-2025-results
47. Medpace Stock Soars After Impressive Q2 Earnings, accessed July 25, 2025, https://stockstotrade.com/news/medpace-holdings-inc-medp-news-2025_07_22-3/
48. Medpace Beats Q2 Revenue Estimates, accessed July 25, 2025, https://www.nasdaq.com/articles/medpace-beats-q2-revenue-estimates
49. Syneos Health (SYNH) | Finance information – Stockcircle, accessed July 25, 2025, https://stockcircle.com/stocks/synh
50. Syneos Health Closes Transaction with Private Investment Firms, accessed July 25, 2025, https://www.syneoshealth.com/news/releases/syneos-health-closes-transaction-private-investment-firms
51. Syneos Health Releases 2025 Health Trends, accessed July 25, 2025, https://www.syneoshealth.com/news/syneos-health-releases-2025-health-trends
52. 2025 Dealmakers’ Intentions Survey – Syneos Health, accessed July 25, 2025, https://www.syneoshealth.com/insights-hub/2025-dealmakers-intentions
53. 2025 Health Trends x The Syneos Health Podcast: A Limited Series Exploring Innovation, Disruption and What’s Next in Global Healthcare, accessed July 25, 2025, https://www.syneoshealth.com/insights-hub/2025-health-trends-x-syneos-health-podcast-limited-series-exploring-innovation
54. First half of 2025: Solid growth, investments and pipeline progress pave the way for two key launches in H2 – Boehringer Ingelheim, accessed July 25, 2025, https://www.boehringer-ingelheim.com/about-us/who-we-are/boehringer-ingelheim-half-year-results-2025
55. Top 10 most anticipated drug launches of 2025 – Fierce Pharma, accessed July 25, 2025, https://www.fiercepharma.com/marketing/top-10-most-anticipated-drug-launches-2025
56. Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping – PR Newswire, accessed July 25, 2025, https://www.prnewswire.com/news-releases/avidity-biosciences-receives-fda-breakthrough-therapy-designation-for-delpacibart-zotadirsen-del-zota-for-the-treatment-of-dmd-in-people-with-mutations-amenable-to-exon-44-skipping-302511334.html
57. Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib – The National Law Review, accessed July 25, 2025, https://natlawreview.com/press-releases/revolution-medicines-announces-fda-breakthrough-therapy-designation-0
58. AI in Pharma and Biotech: Market Trends 2025 and Beyond – Coherent Solutions, accessed July 25, 2025, https://www.coherentsolutions.com/insights/artificial-intelligence-in-pharmaceuticals-and-biotechnology-current-trends-and-innovations
59. Artificial Intelligence (AI) In Drug Discovery Market Insight, Competitive Landscape and Forecasts, 2030 – GlobeNewswire, accessed July 25, 2025, https://www.globenewswire.com/news-release/2024/10/14/2962678/28124/en/Artificial-Intelligence-AI-In-Drug-Discovery-Market-Insight-Competitive-Landscape-and-Forecasts-2030.html
60. Artificial Intelligence (AI) In Drug Discovery Market Size, Share, and Trends 2025 to 2034, accessed July 25, 2025, https://www.precedenceresearch.com/artificial-intelligence-in-drug-discovery-market
61. How Generative AI in Healthcare is Transforming Drug Discovery in 2025 – RFID Journal, accessed July 25, 2025, https://www.rfidjournal.com/expert-views/how-generative-ai-in-healthcare-is-transforming-drug-discovery-in-2025/222589/
62. Decentralized Clinical Trials Market Size & Share | DCT Industry Trends, 2030, accessed July 25, 2025, https://www.mordorintelligence.com/industry-reports/decentralized-clinical-trials-market
63. Decentralized Clinical Trials Guidance: Ultimate 2025 Guide – Lifebit, accessed July 25, 2025, https://lifebit.ai/blog/decentralized-clinical-trials-guidance/
64. Trends in Clinical Trials in 2025: Navigating a Transformative Landscape – Florence, accessed July 25, 2025, https://florencehc.com/blog-post/trends-in-clinical-trials-in-2025-navigating-a-transformative-landscape/
65. Headwinds or Tailwinds: Will the Biotech Sector Rebound in 2025? – DCAT Value Chain Insights, accessed July 25, 2025, https://www.dcatvci.org/features/headwinds-or-tailwinds-will-the-biotech-sector-rebound-in-2025-2/
66. Trendspotting: Predictions for Clinical Research in 2025, accessed July 25, 2025, https://www.clinicalresearchnewsonline.com/news/2025/01/07/trendspotting-predictions-for-clinical-research-in-2025
67. A Focus on Contract Research Organizations (CROs) – CMIC Group, accessed July 25, 2025, https://en.cmicgroup.com/resources/top-5-research-trends-for-2025-a-focus-on-contract-research-organizations-cros/
68. Healthcare Contract Research Organization (CRO) Market Expands …, accessed July 25, 2025, https://www.towardshealthcare.com/insights/healthcare-contract-research-organization-cro-market-sizing
69. Respite from rising trial costs is a distant dream in 2025, accessed July 25, 2025, https://www.clinicaltrialsarena.com/analyst-comment/respite-rising-trial-costs-distant-dream-2025/
70. What’s driving pharma outsourcing in 2025 and beyond? – ECI Partners, accessed July 25, 2025, https://www.ecipartners.com/news-and-insights/insights/2025/what-is-driving-pharma-outsourcing
71. Consolidation in the CRO space a plus for biopharma | BioPharma …, accessed July 25, 2025, https://www.biopharmadive.com/news/cro-cdmo-consolidation-contract-services-pharma-biotech/443492/
72. Stable growth continues in the life sciences VC … – Grant Thornton, accessed July 25, 2025, https://www.grantthornton.com/insights/articles/life-sciences/2025/life-sciences-vc-market
73. Life Sciences Snapshot – Q1 2025 – A Quarterly Report on Financing Trends – Orrick, accessed July 25, 2025, https://media.orrick.com/Media%20Library/public/files/insights/2025/orrick-pitchbook-life-sciences-snapshot-q1-2025.pdf
74. Biopharma Q1 2025: Strategic Shifts and Market … – J.P. Morgan, accessed July 25, 2025, https://www.jpmorgan.com/content/dam/jpmorgan/documents/cb/insights/outlook/jpm-biopharma-deck-q1-2025-final-ada.pdf